IoT Chips Present a $1.08 Trillion Opportunity by 2031 - Global Market Analysis by Hardware, Vertical and Region, Featuring Strategic Insights of Intel, Qualcomm, MediaTek, Samsung Electronics, and More
June 07, 2024 06:54 ET
|
Research and Markets
Dublin, June 07, 2024 (GLOBE NEWSWIRE) -- The "Global IoT Chips Market Size, Share & Trends Analysis Report by Hardware (Processor, Sensor, Connectivity IC, Memory Device, Logic Device and...
Brown & Brown, Inc. acquires the assets of McNamara Company
June 07, 2024 06:45 ET
|
Brown & Brown, Inc.
DAYTONA BEACH, Fla., June 07, 2024 (GLOBE NEWSWIRE) -- J. Scott Penny, chief acquisitions officer of Brown & Brown, Inc. (NYSE:BRO), and Patrick and Aleshia McNamara, principals of McNamara...
Los resultados de última hora del estudio PALOMA-2 de RYBREVANT®▼ (amivantamab) por vía subcutánea en combinación con lazertinib muestran una respuesta antitumoral clínicamente significativa y un perfil de seguridad mejorado en pacientes con cáncer de pulmón no microcítico con mutación del EGFR
June 07, 2024 06:15 ET
|
Janssen Cilag International NV
Se observan reacciones relacionadas con la infusión significativamente menores con la administración subcutánea de amivantamab en comparación con la intravenosa en los nuevos datos de la Fase 21 ...
Les résultats récents de l’étude PALOMA-2 sur RYBREVANT®▼ (amivantamab) administré par voie sous-cutanée en association avec le lazertinib démontrent une réponse antitumorale cliniquement significative et un profil d’innocuité amélioré chez les patients atteints d’un cancer du poumon non à petites cellules avec mutations de l’EGFR
June 07, 2024 06:15 ET
|
Janssen Cilag International NV
Réactions liées à la perfusion nettement moins nombreuses avec l’amivantamab administré par voie sous-cutanée qu’avec l’administration par voie intraveineuse, selon les nouvelles données de la...
Aktuelle Ergebnisse der PALOMA-2-Studie zu subkutan verabreichtem RYBREVANT®▼ (amivantamab) in Kombination mit Lazertinib zeigen klinisch bedeutsames Ansprechen auf den Tumor und verbessertes Sicherheitsprofil bei Patienten mit EGFR-mutiertem nicht-kleinzelligem Lungenkrebs
June 07, 2024 06:15 ET
|
Janssen Cilag International NV
Signifikant weniger infusionsbedingte Reaktionen bei subkutaner Verabreichung von amivantamab im Vergleich zur intravenösen Verabreichung in neuen Phase II Daten1 BEERSE, BELGIEN, June 07, 2024 ...
GameStop Discloses First Quarter 2024 Results
June 07, 2024 06:05 ET
|
GameStop Inc.
GRAPEVINE, Texas, June 07, 2024 (GLOBE NEWSWIRE) -- GameStop Corp. (NYSE: GME) (“GameStop” or the “Company”) today released financial results for the first quarter ended May 4, 2024. The Company’s...
RadNet, Inc. to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024
June 07, 2024 06:00 ET
|
RadNet, Inc.
LOS ANGELES, June 07, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned...
HSBC - Dealings Disclosure - XP Power Limited
June 07, 2024 05:04 ET
|
HSBC Bank Plc
PROPOSED ACQUISITION OF XP POWER LIMITED DEALINGS DISCLOSURE INTRODUCTION The Hongkong and Shanghai Banking Corporation Limited, Singapore Branch ("HSBC") refers to the non-binding cash...
Electric Wheelchair Global Market Opportunities and Strategies to 2033, Featuring Sunrise Medical, Invacare, Permobil, Drive Medical and Ottobock
June 07, 2024 04:35 ET
|
Research and Markets
Dublin, June 07, 2024 (GLOBE NEWSWIRE) -- The "Electric Wheelchair Global Market Opportunities and Strategies to 2033" report has been added to ResearchAndMarkets.com's offering.The global electric...
Global Salt Market Opportunities and Strategies Report 2024-2033: Rock Salt Segment Set to Gain $8.4 Billion of Global Annual Sales by 2028
June 07, 2024 04:34 ET
|
Research and Markets
Dublin, June 07, 2024 (GLOBE NEWSWIRE) -- The "Salt Global Market Opportunities and Strategies to 2033" report has been added to ResearchAndMarkets.com's offering.The global salt market reached a...